Kanada - angleščina - Health Canada

sterimax inc - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Kanada - angleščina - Health Canada

sanofi canada, inc. - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - sympathomimetic (adrenergic) agents

Kanada - angleščina - Health Canada

novopharm limited - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Kanada - angleščina - Health Canada

ivax pharmaceuticals incorporated - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Kanada - angleščina - Health Canada

sandoz canada incorporated - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Irska - angleščina - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - dobutamine - concentrate for solution for infusion - 12.5 milligram(s)/millilitre - adrenergic and dopaminergic agents; dobutamine

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextrose injection, usp is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hainan poly pharm. co., ltd. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine

Združene države Amerike - angleščina - NLM (National Library of Medicine)

slate run pharmaceuticals - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride is contraindic

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath